TOMMY-HILFIGER
6.1.2021 08:32:19 CET | Business Wire | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce that applications for the third edition of the Tommy Hilfiger Fashion Frontier Challenge open from January 6 until March 8, 2021. The global program aims to support entrepreneurial start-up and scale-up stage businesses that develop solutions that make a positive social impact on the fashion landscape. Since its inception in 2018, the Tommy Hilfiger Fashion Frontier Challenge has awarded €350,000 to entrepreneurs who stand up for what they believe in and are committed to driving change within their communities. Building on Tommy Hilfiger’s sustainability vision to Waste Nothing and Welcome All , the third edition of the program strives to amplify and support black, indigenous and people of color (BIPOC) entrepreneurs who are working to advance their communities and foster a more inclusive future of fashion. Consumers are also invited to get involved and help judge submissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105006033/en/
“The Tommy Hilfiger Fashion Frontier Challenge puts a spotlight on entrepreneurs putting their heart and soul into making a positive social impact in our industry,” said Tommy Hilfiger. “This year, we want to showcase an even more diverse range of perspectives, ideas and communities by supporting BIPOC entrepreneurs. We have a responsibility to drive change across the fashion landscape, and I am honored to further our commitment to inclusivity and equal representation through the upcoming Tommy Hilfiger Fashion Frontier Challenge.”
Interested businesses are invited to submit project proposals that focus on creating a more inclusive fashion value-chain. Applicants will be narrowed down to six finalists who will be invited to develop their project plans virtually with the support of dedicated Tommy Hilfiger and external subject-matter experts. With training from an experienced pitch coach, finalists will present their final concept to a prestigious jury panel and associate audience at the global Tommy Hilfiger Fashion Frontier Challenge final event to be held in early 2022.
In a bid to further its ambitions of inclusivity, Tommy Hilfiger has extended an invitation to consumers to join in as Consumer Judges and help decide this year’s finalists. Consumer Judges will be tasked with narrowing down finalists from 200 to 50, with each being sent at least four applications to judge via the brand’s online microsite. Applications to become a Consumer Judge can be made through https://responsibility.pvh.com/tommy/fashion-frontier-challenge/ and close February 8th.
The following program prizes have been increased from previous years, providing winners with the finance and knowledge to grow their business idea:
- A total of €200,000 awarded between winners and a chance at an additional €15,000 prize for winning the “Audience Favorite Vote”
- A year-long mentorship with global Tommy Hilfiger’s internal experts,
- A place on the INSEAD Social Entrepreneurship Program (ISEP)
- A year-long INSEAD mentorship
“While the fashion industry has taken positive steps towards becoming more inclusive and diverse, there is still more to be done,” said Martijn Hagman, CEO, Tommy Hilfiger Global. “Through the Tommy Hilfiger Fashion Frontier Challenge, we are furthering our commitment towards representation and diversity and helping drive the changes we most want, and need, to see.”
Tommy Hilfiger’s mission is to become a fashion company that Wastes Nothing and Welcomes All ; a leading sustainable designer lifestyle company through how it creates its product, manages its operations, and connects with its communities and stakeholders. More information about Tommy Hilfiger’s sustainability journey, which is powered by PVH’s Forward Fashion strategy, can be found on https://global.tommy.com/en_int/about-us-corporate-sustainability .
More information about the Tommy Hilfiger Fashion Frontier Challenge , including how to apply, is available here: https://responsibility.pvh.com/tommy/fashion-frontier-challenge/ .
Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger, and @TommyHilfiger.
# # #
About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER and TOMMY JEANS , Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER and TOMMY JEANS brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER and TOMMY JEANS retail stores, leading specialty and department stores, select online retailers, and at tommy .com.
About PVH Corp.
PVH is one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our brand portfolio includes the iconic Calvin Klein , TOMMY HILFIGER , Van Heusen , IZOD , ARROW, Warner’s , Olga and Geoffrey Beene brands, as well as the digital-centric True&Co. intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 40,000 associates operating in over 40 countries and $9.9 billion in annual revenues. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105006033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
